Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIKI NASDAQ:DKDCA NASDAQ:LUNA NASDAQ:MDXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIKIAIkido Pharma$4.55+3.3%$5.17$3.31▼$11.48$19.53M0.9379,326 shs217,880 shsDKDCAData Knights Acquisition$0.48-2.9%$0.47$5.00▼$13.51$2.50M0.1839,705 shs62,083 shsLUNALuna Innovations$1.00$0.82$0.22▼$3.11$33.96M1.96167,434 shs504 shsMDXHMDxHealth$2.43+1.7%$2.21$1.35▼$3.50$113.02M1.4160,566 shs192,290 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIKIAIkido Pharma-10.96%-8.63%-13.83%-19.61%+155.62%DKDCAData Knights Acquisition0.00%-9.64%-6.12%+17.24%-66.88%LUNALuna Innovations0.00%0.00%+11.11%+150.00%-66.67%MDXHMDxHealth+1.67%-2.41%+9.95%+41.28%-13.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIKIAIkido PharmaN/AN/AN/AN/AN/AN/AN/AN/ADKDCAData Knights AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ALUNALuna Innovations0.2294 of 5 stars0.03.00.00.00.01.70.0MDXHMDxHealth2.7999 of 5 stars3.55.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIKIAIkido Pharma 0.00N/AN/AN/ADKDCAData Knights Acquisition 0.00N/AN/AN/ALUNALuna Innovations 0.00N/AN/AN/AMDXHMDxHealth 3.00Buy$7.00188.07% UpsideCurrent Analyst Ratings BreakdownLatest AIKI, LUNA, DKDCA, and MDXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025MDXHMDxHealthCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIKIAIkido PharmaN/AN/AN/AN/A$19.27 per shareN/ADKDCAData Knights AcquisitionN/AN/A$0.00 per share111.42($1.82) per shareN/ALUNALuna Innovations$116.61M0.29$0.33 per share3.03N/A∞MDXHMDxHealth$90.05M1.28N/AN/A$0.31 per share7.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIKIAIkido Pharma-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/ADKDCAData Knights Acquisition$340K-$0.19N/A∞N/AN/AN/A-5.55%N/ALUNALuna Innovations$9.28MN/A0.00∞N/AN/AN/AN/AN/AMDXHMDxHealth-$38.07M-$1.15N/AN/AN/A-41.02%-492.11%-23.00%8/20/2025 (Estimated)Latest AIKI, LUNA, DKDCA, and MDXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025MDXHMDxHealth-$0.13N/AN/AN/AN/AN/A5/14/2025Q1 2025MDXHMDxHealth-$0.13-$0.19-$0.06-$0.19$22.62 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIKIAIkido PharmaN/AN/AN/AN/AN/ADKDCAData Knights AcquisitionN/AN/AN/AN/AN/ALUNALuna InnovationsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIKIAIkido PharmaN/A29.5429.54DKDCAData Knights AcquisitionN/AN/AN/ALUNALuna InnovationsN/AN/AN/AMDXHMDxHealth13.812.001.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIKIAIkido Pharma10.88%DKDCAData Knights Acquisition35.35%LUNALuna Innovations87.46%MDXHMDxHealthN/AInsider OwnershipCompanyInsider OwnershipAIKIAIkido Pharma8.60%DKDCAData Knights Acquisition45.72%LUNALuna Innovations7.60%MDXHMDxHealth1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIKIAIkido Pharma45.49 million5.01 millionNot OptionableDKDCAData Knights Acquisition25.17 million2.81 millionNot OptionableLUNALuna Innovations39033.96 million31.38 millionOptionableMDXHMDxHealth30047.29 million46.48 millionNot OptionableAIKI, LUNA, DKDCA, and MDXH HeadlinesRecent News About These CompaniesMDxHealth SA (NASDAQ:MDXH) Shares Acquired by Perkins Capital Management Inc.July 28, 2025 | marketbeat.comMDxHealth (NASDAQ:MDXH) Now Covered by Craig HallumJuly 17, 2025 | marketbeat.comMDxHealth (NASDAQ:MDXH) Trading 0.5% Higher - Should You Buy?July 15, 2025 | marketbeat.comMDxHealth names Michael Holder to board, CFO Ron Kalfus to departJuly 5, 2025 | investing.comMDxHealth Appoints Michael Holder as Chair of Audit Committee, Announces CFO Transition - NasdaqJuly 5, 2025 | nasdaq.comMDxHealth CFO Kalfus ResignsJuly 3, 2025 | marketwatch.comMdxhealth Appoints Michael Holder to Board of Directors and Announces Management ChangeJuly 3, 2025 | globenewswire.comMDXHEALTH SA Earnings Results: $MDXH Reports Quarterly EarningsMay 16, 2025 | nasdaq.comMDxHealth Q1 Revenues Leap 22 PercentMay 15, 2025 | 360dx.com3MDxHealth SA (MDXH) Q1 2025: Everything You Need to Know Ahead of EarningsMay 15, 2025 | finance.yahoo.comMDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comMDxHealth Reports Q1-2025 ResultsMay 14, 2025 | globenewswire.comMdxhealth to Release First Quarter 2025 Financial Results on May 14April 30, 2025 | manilatimes.netMLake Street Reaffirms Their Buy Rating on MDxHealth (MDXH)April 5, 2025 | markets.businessinsider.comMDxHealth management to meet with Lake StreetMarch 27, 2025 | markets.businessinsider.comDown -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)March 6, 2025 | zacks.comEarnings call transcript: MDxHealth beats Q4 2024 EPS forecast, stock risesFebruary 28, 2025 | investing.comMDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue EstimatesFebruary 26, 2025 | zacks.comMdxhealth Announces Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 26, 2025 | globenewswire.comMdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26February 12, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)January 15, 2025 | markets.businessinsider.comMedia Sentiment Over TimeAIKI, LUNA, DKDCA, and MDXH Company DescriptionsAIkido Pharma NASDAQ:AIKI$4.55 +0.15 (+3.29%) As of 07/31/2025AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Data Knights Acquisition NASDAQ:DKDCA$0.48 -0.01 (-2.91%) As of 07/29/2025Data Knights Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. Data Knights Acquisition Corp. was incorporated in 2021 and is based in Frome, the United Kingdom.Luna Innovations NASDAQ:LUNA$1.00 0.00 (0.00%) As of 07/31/2025 12:49 PM EasternLuna Innovations Incorporated provides fiber optic test, measurement, and control products worldwide. The company offers test and measurement equipment for fiber optic components and sub-assemblies; polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; and single frequency lasers. It also provides ODiSI sensing solution, which provides distributed strain and temperature measurements; distributed temperature sensing system; hyperion sensing products; Terahertz Sensing Systems that provide precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; and distributed acoustic sensing products. The company primarily markets its fiber optic test, measurement, and control products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.MDxHealth NASDAQ:MDXH$2.43 +0.04 (+1.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.38 -0.06 (-2.26%) As of 08/1/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
